布帕伐醌

更新时间:2024-01-02 22:22:16

布帕伐醌结构式
布帕伐醌结构式
品牌特惠专场
常用名 布帕伐醌 英文名 Buparvaquone
CAS号 88426-33-9 分子量 326.429
密度 1.2±0.1 g/cm3 沸点 460.7±45.0 °C at 760 mmHg
分子式 C21H26O3 熔点 178-184ºC
MSDS 中文版 美版 闪点 246.5±25.2 °C

 布帕伐醌用途


Buparvaquone是一种与parvaquone和atovaquone有关的羟基萘醌类抗原虫药。

 布帕伐醌名称

中文名 布帕伐醌
英文名 3-[(4-tert-butylcyclohexyl)methyl]-4-hydroxynaphthalene-1,2-dione
中文别名 2-[(4-叔丁基环己基)甲基]-3-羟基-1,4-萘二酮
英文别名 更多

 布帕伐醌生物活性

描述 Buparvaquone是一种与parvaquone和atovaquone有关的羟基萘醌类抗原虫药。
相关类别
体外研究 在4天的增殖试验中,buparvaquone有效抑制犬新孢子虫的速殖子复制(IC50 = 4.9 nM; IC100 = 100 nM)[1]。 Buparvaquone对L.(L.)infantum chagasi细胞内无鞭毛体具有显着选择性,IC50值为1.5μM。其他皮肤物种也对buparvaquone敏感,IC50值在1-4μM范围内[2]。
体内研究 用腹腔注射或强饲法治疗犬新型犬(100 mg/kg)对犬新孢子虫感染的小鼠,在腹腔注射治疗组的6只小鼠中有4只预防新孢子虫症状,在接受口服治疗的7只小鼠中有6只[ 1]。与未处理对照相比,buparvaquone的含水凝胶和油包水乳液均可显着降低皮肤寄生虫负荷和病变大小[3]。
细胞实验 为了研究入侵前宿主细胞的预处理是否对寄生虫增殖有任何影响,将6孔板中生长的融合HFF用1μMBuparvaquone在培养基中处理1小时或5小时,并将对照暴露于相应量的DMSO 。随后,除去含药物的培养基,用Hank's平衡盐溶液将单层细胞洗涤4次,并在5mL培养基中用Nc-Liv速殖子感染,不含任何药物或溶剂。 2天后,用细胞刮刀收集细胞,离心,再用PBS洗涤一次,然后将沉淀储存在-20℃,然后通过犬新孢子虫特异性实时PCR定量犬新孢子虫增殖,如下所述[1]。
动物实验 小鼠:在第0天,通过腹膜内(ip)注射新鲜纯化的犬新孢子虫速殖子感染所有小鼠。 48小时后,小鼠通过腹膜内注射100μl体积或通过管饲口服施用100μl,接受BPQ(100mg / kg)作为玉米油中的悬浮液。对照组仅ip或口服获得相应量的溶剂(参见表2)。治疗每天进行5次。如果没有另外说明,则每天两次检查小鼠的临床症状(皱褶外套,冷漠,后肢麻痹),直至感染后第21天(pi),此时将其安乐死[1]。
参考文献

[1]. Müller J, et al. Buparvaquone is active against Neospora caninum in vitro and in experimentally infected mice. Int J Parasitol Drugs Drug Resist. 2015 Feb 13;5(1):16-25.

[2]. Reimão JQ, et al. Effectiveness of liposomal buparvaquone in an experimental hamster model of Leishmania (L.) infantum chagasi. Exp Parasitol. 2012 Mar;130(3):195-9.

[3]. Garnier T, et al. In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs. J Antimicrob Chemother. 2007 Oct;60(4):802-10.

 布帕伐醌物理化学性质

密度 1.2±0.1 g/cm3
沸点 460.7±45.0 °C at 760 mmHg
熔点 178-184ºC
分子式 C21H26O3
分子量 326.429
闪点 246.5±25.2 °C
精确质量 326.188202
PSA 54.37000
LogP 6.45
外观性状 黄色结晶固体
蒸汽压 0.0±1.2 mmHg at 25°C
折射率 1.574
储存条件 Refrigerator

 布帕伐醌毒性和生态

 布帕伐醌安全信息

危险品运输编码 NONH for all modes of transport
RTECS号 QJ5766600

 布帕伐醌文献25

更多文献
Drug delivery systems for the topical treatment of cutaneous leishmaniasis.

Expert Opin. Drug Deliv. 9(9) , 1083-97, (2012)

The parenteral administration of pentavalent antimonials for the treatment of all forms of leishmaniasis, including cutaneous leishamniasis (CL), has several limitations. Therapy is long, requiring re...

In-vivo therapeutic efficacy trial with artemisinin derivative, buparvaquone and imidocarb dipropionate against Babesia equi infection in donkeys.

J. Vet. Med. Sci. 65(11) , 1171-7, (2003)

The therapeutic efficacy of imidocarb, artesunate, arteether, buparvaquone and arteether+buparvaquone combination was evaluated against Babesia equi of Indian origin in splenectomised donkeys with exp...

Design, synthesis and in vitro evaluation of novel water-soluble prodrugs of buparvaquone.

Eur. J. Pharm. Sci. 23(2) , 151-8, (2004)

Novel water-soluble phosphate prodrugs (2b-5b) of buparvaquone-oxime (1a) and buparvaquone-O-methyloxime (1b) were synthesized and evaluated in vitro as potential oral prodrugs against leishmaniasis. ...

 布帕伐醌英文别名

2-[(4-tert-butylcyclohexyl)methyl]-3-hydroxynaphthalene-1,4-dione
2-[[4-(1,1-Dimethylethyl)cyclohexyl]methyl]-3-hydroxy-1,4-naphthalenedione
Butalex
UNII-0354RT7LG4
1,4-Naphthalenedione, 2-[[4-(1,1-dimethylethyl)cyclohexyl]methyl]-3-hydroxy-
2-[(4-tert-Butylcyclohexyl)methyl]-3-hydroxynaphthalen-1,4-dion
2-((4-tert-Butylcyclohexyl)methyl)-3-hydroxy-1,4-naphthochinon
BW 720C
Buparvaquone
Buparvaquonum [Latin]
Buparvacuona [Spanish]
3-(4-t-Butylcyclohexyl)methyl-2-hydroxy-1,4-naphthoquinone
MFCD01712789
2-((4-(1,1-Dimethylethyl)cyclohexyl)methyl)-3-hydroxy-1,4-naphthalenedione
2-[(4-tert-Butylcyclohexyl)methyl]-3-hydroxy-1,4-naphthoquinone
2-Hydroxy-3-{[4-(2-methyl-2-propanyl)cyclohexyl]methyl}-1,4-naphthoquinone
2-((4-tert-Butylcyclohexyl)methyl)-3-hydroxy-1,4-naphthoquinone
1,4-Naphthalenedione, 2-((4-(1,1-dimethylethyl)cyclohexyl)methyl)-3-hydroxy-
品牌现货直购
推荐供应商:







查看所有供应商和价格请点击:

布帕伐醌生产厂家

布帕伐醌价格